Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Pharmaceuticals, Inc.

http://www.regeneron.com

Latest From Regeneron Pharmaceuticals, Inc.

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

South Korea Financing

Ambitious Almirall Lays Out Ebglyss Launch Plans

The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.

Dermatology Launches

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.

Ophthalmic Clinical Trials

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

Approvals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Checkmate Pharmaceuticals, Inc.
    • Regeneron Genetics Center LLC (RGC)
UsernamePublicRestriction

Register